Oncology Articles

Intriguing Immunotherapy Regimens Investigated in MCL
Grzegorz S. Nowakowski, MD, discusses the ever-changing landscape of mantle cell lymphoma, the intriguing combinations being studied, and the promise that immunotherapy could hold.
FDA Grants Lorlatinib Breakthrough Designation for NSCLC
The FDA has granted a breakthrough therapy designation to lorlatinib for use in patients with ALK-positive metastatic NSCLC who have previously received 1 or more ALK inhibitors, according to Pfizer, the company developing the next-generation ALK/ROS1 TKI.
Immunotherapy Demonstrates Early Promise Across Lymphoma Subgroups
Stephen M. Ansell, MD, PhD, discusses the potential of immunotherapy agents in lymphoma, ongoing clinical trials, and where this blends in with chimeric antigen receptor (CAR) T-cell therapy.
FDA Approves Regorafenib for Liver Cancer
The FDA has approved regorafenib (Stivarga) as a second-line treatment for patients with hepatocellular carcinoma (HCC) who have previously received sorafenib (Nexavar).
Comprehensive Genomic Profiling Could Improve Diagnoses, Treatment in Sarcoma
Researchers at MD Anderson Cancer Center believe that including clinical genomic profiling into sarcoma management could result in more precise diagnosis and subclassification of the disease.
EU Grants Full Approval to Osimertinib for EGFR T790M-Positive NSCLC
The European Union has granted a full approval to osimertinib (Tagrisso) for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive non–small cell lung cancer, regardless of prior treatment with an EGFR TKI.
Abiraterone Shows Promise in Prostate Cancer After Hormone Induction Failure
Thomas Flaig, MD, discusses the study of abiraterone acetate in metastatic prostate cancer after hormone induction failure and its impact on future research in this setting.
Expert Addresses Issues in Advanced Gynecologic Cancers
Dana Chase, MD, discusses obstacles to progress and her hope for the future in advanced gynecologic cancers.
European Commission Approves Oral Rolapitant for CINV
The European Commission has approved oral rolapitant tablets for the treatment of delayed chemotherapy-induced nausea and vomiting in adults.
Biomarker Testing in NSCLC to Expand in Near Future
Matthew Gubens, MD, discusses how far the field of NSCLC has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.
Publication Bottom Border
Border Publication